Cimedical
Cimedical is a Barranquilla-based clinical research organization and healthcare provider conducting Phase I-IV trials, bioequivalence studies, and patient care in rheumatology and chronic disease for global pharma sponsors and CROs such as IQVIA, PPD, and Novartis.
- Company typePrivate
- Founded1993
- HeadquartersBarranquilla, Colombia
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Cimedical does
Cimedical (legal name Centro de Investigación Médico Asistencial SAS) is a Barranquilla, Colombia-based clinical research organization and healthcare services provider (Institución Prestadora de Servicios, IPS) operating from a single site since 1993 and active in industry-sponsored clinical research since 2007. Its core offerings span Phase I-IV interventional trials, observational studies, and bioavailability/bioequivalence studies executed on behalf of pharmaceutical sponsors and CROs; a parallel patient-care practice delivering rheumatology, internal medicine, orthopedics, dermatology, and telemedicine services; and an independent Research Ethics Committee (CEI) that audits, trains, and reviews protocols for the site and external clients. The product layer is anchored by CIMA 2.0, a proprietary in-house electronic medical record and clinical history platform, complemented by a 100% digital Ethics Committee review portal; both are partially funded by a 190 million COP ICONOS grant from the Atlántico Governorate and ACOPI.
Cimedical runs its own hospitalization infrastructure (over 500 m2, 26 beds across 3 rooms) dedicated in part to bioequivalence work, and has accumulated 36 registered clinical trials covering rheumatology, nephrology, cardiology, dermatology, pulmonology, immunology, and infectious diseases including lupus, rheumatoid arthritis, asthma, and dengue. The model is sales-led and professional-services-based: revenue is generated through per-contract engagements with sponsors such as AstraZeneca, Pfizer, Novartis, Roche, Janssen, Biogen, Sanofi, GSK, Amgen, and AbbVie, routed via global CRO partners including IQVIA, PPD, PRA Health Sciences, Worldwide Clinical Trials, and ICON, plus direct bioequivalence engagements with manufacturers such as PROCAPS SA. The site is INVIMA-certified in Good Clinical Practices (May 2025) and Good Bioavailability/Bioequivalence Practices, and is registered with the US Office for Human Research Protections (OHRP-IRB).
The differentiation rests on regulatory certifications, a specialized multi-therapeutic investigator team with over 20 years of research experience, dedicated bioequivalence infrastructure, and an in-house digital platform stack, all concentrated in a single regional market on Colombia's Caribbean coast. As of January 2026 the organization added an inaugural Chief AI Officer role (Dr. Adil Haider), but no AI products, models, or revenue from AI-enabled services have been disclosed.
Cimedical firmographics
Firmographics- Name
- Cimedical
- Legal name
- CENTRO DE INVESTIGACIÓN MEDICO ASISTENCIAL SAS
- Website
- https://cimedical.co
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cimedical is a Barranquilla-based clinical research organization and healthcare provider conducting Phase I-IV trials, bioequivalence studies, and patient care in rheumatology and chronic disease for global pharma sponsors and CROs such as IQVIA, PPD, and Novartis.
- Ownership category
- akta.pro rank
Cimedical industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- General Medical and Surgical Hospitals (62211)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Laboratory LIS (Core Lab/Hospital Lab) (HLACAMAA)
Keywords
Where Cimedical is headquartered
LocationHeadquarters
- HQ city
- Barranquilla
- HQ country
- Colombia
- HQ region
- Latin America
Offices3 records
Markets served
Cimedical business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Clinical Trial Services: Revenue generated from conducting Phase I-IV interventional clinical trials and observational studies for pharmaceutical companies. Services include protocol development, clinical stage execution, bioanalytical services, biostatistical analysis, and final reporting.
- Bioavailability and Bioequivalence Studies: Specialized studies to establish bioequivalence of pharmaceutical products against reference products for regulatory approval. Covers full study lifecycle from protocol development through clinical and bioanalytical phases to final reporting.
- Healthcare/Assistance Services: Primary and specialized healthcare services including rheumatology, internal medicine, orthopedics, physiotherapy, laboratory tests, densitometry, infusion room, vaccination, and telemedicine services.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Cimedical product offering
Product offeringCore offering
Cimedical is a clinical research center and healthcare services provider in Barranquilla, Colombia, offering Phase I-IV interventional clinical trials, observational studies, bioavailability/bioequivalence studies, and patient care services. The company operates its proprietary CIMA 2.0 electronic clinical history platform to support research data management, while serving pharmaceutical sponsors and CROs alongside individual patients requiring specialized care.
Product overview
Cimedical is a medical research and healthcare institution (IPS) offering a unified platform of clinical research services and electronic health records. The core offering centers on CIMA 2.0, its electronic medical record platform, complemented by the CIMA Portal for system access. Services span interventional and observational clinical trials, bioavailability/bioequivalence studies, healthcare/patient care, and ethics committee services. The institution operates clinical studies across multiple therapeutic areas including rheumatology, cardiology, dermatology, nephrology, pneumology, and infectious diseases, with a focus on autoimmune diseases and chronic conditions.
Differentiator
Problem solved
Functional benefit
Brands
- CIMA 2.0: Electronic clinical history platform developed by Cimedical for medical records management.
Products and services
- Interventional Clinical Studies Services
Quantifiable outcome
- Top Recruiter in Colombia to the PRO2TECT program from AKEBIA
- +3 more outcomes
Companies that use Cimedical
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles2 records
Cimedical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Cimedical partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered core and minor.
- AstraZenecacorePharmaceutical company partnership for clinical trial sponsorship. Cimedical has conducted AstraZeneca-sponsored studies including Asthma Severa study (2018). AstraZeneca is listed among the pharmaceutical allies on the clinical studies page.
- Boehringer IngelheimcorePharmaceutical company partnership for clinical trial sponsorship including Insuficiencia Cardíaca study (2017). Listed as pharmaceutical ally for clinical research.
- JanssencorePharmaceutical company partnership for clinical trials including Covid-19 (2020) and Dengue (2023) studies. Listed as pharmaceutical ally with multiple study engagements.
- NovartiscoreLong-standing pharmaceutical partnership including multiple studies in Espondilitis Anquilosante (2018, 2020), Artritis Reumatoide (2012), Psoriasis (2012), and Urticaria (2022).
- PfizercorePharmaceutical partnership for clinical trials including Prevalencia A Insuficiencia Cardíaca study (2019) and Artritis Reumatoide studies (2010, 2013).
- RochecorePharmaceutical partnership for clinical trial sponsorship including Artritis Reumatoide study (2012).
- SanoficorePharmaceutical partnership including Dermatitis Atópica study (2019) under Sanofi Aventis brand.
- BiogencoreLong-standing partnership for multiple lupus and nephritis studies (Nefritis Lúpica 2012, 2014; Lupus Eritematoso Sistémico 2018).
- IQVIA (QuintilesIMS)coreGlobal CRO partnership. Awarded 'Achievement of Excellence 2017' recognition. IQVIA is listed as CRO ally providing regulatory and research support.
- PPDcoreCRO partnership for clinical trial support. PPD is listed among CRO allies on the clinical studies page.
- PRA Health SciencescoreCRO partnership for clinical trial operations. Listed among CRO allies on the clinical studies page.
- Worldwide Clinical TrialscoreCRO partnership for clinical trial support. Listed among CRO allies on the clinical studies page.
- AbbViecorePharmaceutical partnership listed among allies on the clinical studies page.
- AmgencorePharmaceutical partnership for Osteoporosis studies (2013, 2015). Listed among pharmaceutical allies.
- GlaxoSmithKline (GSK)corePharmaceutical partnership for Lupus Eritematoso Sistémico (2012) and Artritis Reumatoide (2020) studies.
- MerckcorePharmaceutical partnership listed among allies on the clinical studies page.
- PROCAPS SAcoreBioequivalence study sponsorship for Metformina 1000mg tablet study (2018). PROCAPS is a Colombian pharmaceutical company.
- OHRP-IRBS-IRBcoreUS Office for Human Research Protections registration providing international backing for research ethics standards. Cimedical maintains active international partnerships through this IRB registration.
- ICONminorCRO partner listed among allies on the clinical studies page.
- PharmascienceminorPharmaceutical company partner for bioequivalence studies, featured on the bioequivalence page.
- Gobernación del AtlánticocoreGovernment partner that co-funded the CIMA 2.0 platform development through the ICONOS grant program along with ACOPI.
- ACOPIcoreBusiness association partner providing co-funding for innovation through the ICONOS grant program with the Atlántico Governorate.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Cimedical competitors and assessment
Company assessmentDirect peers
- Worldwide Clinical Trials: Worldwide Clinical Trials is a global CRO listed as one of Cimedical's CRO allies. It provides Phase I-IV clinical trial services with strong capabilities in bioequivalence and early-phase work—directly overlapping with Cimedical's core offerings.
Broad incumbents
- IQVIA: IQVIA is the world's largest CRO and is both a Cimedical partner (CIMEDICAL has worked with IQVIA/QuintilesIMS for years) and a competitor. IQVIA operates site services globally and provides direct comparator to Cimedical's clinical trial and bioequivalence services, though at vastly larger scale.
- PPD (Thermo Fisher Scientific): PPD is one of Cimedical's listed CRO partners and a major global CRO now owned by Thermo Fisher Scientific. PPD operates across all clinical phases and competes with Cimedical for outsourced clinical trial execution in Latin America.
- ICON plc: ICON plc is a global CRO that acquired PRA Health Sciences and is listed as one of Cimedical's CRO partners. ICON runs Phase I-IV trials globally and competes with Cimedical for pharma-sponsored Latin American trial placements.
- Medpace: Medpace is a mid-to-large global CRO providing full-service Phase I-IV clinical trial management. Medpace operates across Latin America and competes with Cimedical for pharma-sponsored trial placement, though at meaningfully larger scale.
- Charles River Laboratories: Charles River Laboratories provides early-stage CRO services, bioequivalence/biopharmaceutics research, and safety assessment. Comparable to Cimedical in the bioequivalence and bioanalytical dimension, though serving a global client base across multiple geographies.
- Parexel International: Parexel is a major global CRO offering Phase I-IV clinical trial services and biopharmaceutical solutions. Comparable to Cimedical in core clinical trial execution but operating globally at much larger scale, with established Latin American site network capabilities.
Emerging players
- Clinipace Worldwide: Clinipace Worldwide is a mid-sized CRO focused on emerging biopharma and adaptive clinical trial design. Comparable to Cimedical as a contract clinical research services provider, though more technology-enabled and serving a broader client mix.
Market position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cimedical social profiles
Digital presenceCimedical compliance and trust
Trust signalCompliance7 records
Cimedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cimedical leadership team
Management profileNumber of profiles
Profiles1 record
Cimedical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cimedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cimedical
What does Cimedical do?
Cimedical is a clinical research center and healthcare services provider in Barranquilla, Colombia, offering Phase I-IV interventional clinical trials, observational studies, bioavailability/bioequivalence studies, and patient care services. The company operates its proprietary CIMA 2.0 electronic clinical history platform to support research data management, while serving pharmaceutical sponsors and CROs alongside individual patients requiring specialized care.
Is Cimedical a public or private company?
Cimedical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cimedical founded?
Cimedical was founded in 1993. It employs 11 to 50 people.
Where is Cimedical based?
Cimedical is headquartered in Barranquilla, Colombia, in the Latin America region.
How does Cimedical make money?
Three revenue lines are on record. Clinical Trial Services are the primary driver. The others are bioavailability and Bioequivalence Studies and healthcare/Assistance Services.
Who are Cimedical's main competitors?
Worldwide Clinical Trials is listed as a direct peer. Broad incumbents are IQVIA, PPD (Thermo Fisher Scientific), ICON plc, Medpace, Charles River Laboratories and Parexel International. Clinipace Worldwide is listed as an emerging player.
Does Cimedical have an API?
No public API is recorded for Cimedical.
What industry is Cimedical in?
Cimedical's product category is Clinical Research Services. Its primary akta.pro industry code is HLACAMAA, Clinical Laboratory LIS (Core Lab/Hospital Lab). Its NAICS code is 62211 and its SIC code is 8011.